In 2017, the genetic risk assessment of AML was updated by European Leukemia Network and classified as favorable, intermediate, and adverse groups.6 Biallelic CEBPA mutation and NPM1 mutation without FLT3-ITD or with FLT3-ITDlow are the genetic variations classified in the favorable group. This evidence concerns the gene FLT3 and acute myeloid leukemia.